Paper36097193
Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype.
Kang S and 6 others. Oncogene, 2022. Cited by 16 papers, by iCite.
Cite this record
ConductScience Library. Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype. Papers, record 36097193. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36097193
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antigens, Neoplasm | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| T-Lymphocytes | Major topic |
| Animals | |
| Cell Line, Tumor | |
| Decitabine | |
| Humans | |
| Membrane Proteins | |
| Mice | |
| Phenotype | |
| Receptors, Antigen, T-Cell | |
| Receptors, CCR7 | |
| Tumor Necrosis Factor-alpha |
Source PubMed
References59
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32249005 | Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive models. | Blood Rev | 2020 | https://conductscience.org/library/papers/32249005 | PubMed |
| 2 | 30626574 | Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors. | Blood Adv | 2019 | https://conductscience.org/library/papers/30626574 | PubMed |
| 3 | 26031916 | Efficiency of high-dose cytarabine added to CY/TBI in cord blood transplantation for myeloid malignancy. | Blood | 2015 | https://conductscience.org/library/papers/26031916 | PubMed |
| 4 | 23478054 | Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23478054 | PubMed |
| 5 | 30578254 | Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. | Blood | 2019 | https://conductscience.org/library/papers/30578254 | PubMed |
| 6 | 29567707 | CAR T cell immunotherapy for human cancer. | Science | 2018 | https://conductscience.org/library/papers/29567707 | PubMed |
| 7 | 30622438 | T cell receptor-engineered T cells for leukemia immunotherapy. | Cancer Cell Int | 2019 | https://conductscience.org/library/papers/30622438 | PubMed |
| 8 | 28860210 | Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. | Blood | 2017 | https://conductscience.org/library/papers/28860210 | PubMed |
| 9 | 29972754 | Chimeric Antigen Receptor Therapy. | N Engl J Med | 2018 | https://conductscience.org/library/papers/29972754 | PubMed |
| 10 | 29155426 | CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. | Nat Med | 2018 | https://conductscience.org/library/papers/29155426 | PubMed |
| 11 | 27111235 | CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. | J Clin Invest | 2016 | https://conductscience.org/library/papers/27111235 | PubMed |
| 12 | 32435621 | CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions. | Front Oncol | 2020 | https://conductscience.org/library/papers/32435621 | PubMed |
| 13 | 31235963 | T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. | Nat Med | 2019 | https://conductscience.org/library/papers/31235963 | PubMed |
| 14 | 27776339 | Generation of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies. | Oncotarget | 2016 | https://conductscience.org/library/papers/27776339 | PubMed |
| 15 | 21282551 | Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21282551 | PubMed |
| 16 | 11351307 | Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. | Int J Cancer | 2001 | https://conductscience.org/library/papers/11351307 | PubMed |
| 17 | 25538264 | A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. | Clin Cancer Res | 2015 | https://conductscience.org/library/papers/25538264 | PubMed |
| 18 | 30546433 | Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: A case report. | Oncol Lett | 2018 | https://conductscience.org/library/papers/30546433 | PubMed |
| 19 | 31289029 | Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. | Blood Adv | 2019 | https://conductscience.org/library/papers/31289029 | PubMed |
| 20 | 26193344 | NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. | Nat Med | 2015 | https://conductscience.org/library/papers/26193344 | PubMed |
Cited by13
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42925407 | Decitabine and azacitidine exert multifaceted effects beyond DNA hypomethylation in myeloid neoplasms. | Int J Hematol | 2026 | https://conductscience.org/library/papers/42925407 | PubMed |
| 42480219 | Long-acting pegylated interferon gamma sensitizes AML cells to killing by donor T cells. | Blood Adv | 2026 | https://conductscience.org/library/papers/42480219 | PubMed |
| 42288680 | Targeting mitochondrial TRIP13-AIF interaction suppresses myeloid leukemia progression and overcomes drug resistance. | Oncogene | 2026 | https://conductscience.org/library/papers/42288680 | PubMed |
| 42194057 | Mechanism and Therapeutic Potential of Viral Mimicry in Cancer Immunotherapy. | Biomolecules | 2026 | https://conductscience.org/library/papers/42194057 | PubMed |
| 41986386 | Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial. | Nat Commun | 2026 | https://conductscience.org/library/papers/41986386 | PubMed |
| 41769689 | Comparison of maintenance with decitabine or chemotherapy in a real-world cohort of patients with acute myeloid leukemia. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/41769689 | PubMed |
| 41768369 | Immune Exhaustion in Chronic Infection and Cancer: Signaling Pathways and Therapeutic Interventions. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/41768369 | PubMed |
| 40664662 | Combining decitabine with radiotherapy to enhance nasopharyngeal carcinoma radiosensitivity via the TFAP2C-OTUD1-SLC25A11 axis. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/40664662 | PubMed |
| 40140361 | BH3 mimetics augment cytotoxic T cell killing of acute myeloid leukemia via mitochondrial apoptotic mechanism. | Cell Death Discov | 2025 | https://conductscience.org/library/papers/40140361 | PubMed |
| 39813621 | Current developments in T-cell receptor therapy for acute myeloid leukemia. | Blood Adv | 2025 | https://conductscience.org/library/papers/39813621 | PubMed |
| 38711501 | Higher TIGIT+ γδ TCM cells may predict poor prognosis in younger adult patients with non-acute promyelocytic AML. | Front Immunol | 2024 | https://conductscience.org/library/papers/38711501 | PubMed |
| 37228497 | Gene mutation landscape of a rare patient with acute megakaryoblastic leukemia after treatment of intracranial germ cell tumor. | Front Oncol | 2023 | https://conductscience.org/library/papers/37228497 | PubMed |
| 37153607 | The magic of small-molecule drugs during ex vivo expansion in adoptive cell therapy. | Front Immunol | 2023 | https://conductscience.org/library/papers/37153607 | PubMed |
Genes22
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36097193
GET https://conductscience.org/api/papers/v1/36097193/references?page=2